Table 2.

Summary of vedolizumab trials.

Study	Sample size	Treatment arms	Clinical remission (%)	Clinical response (%)	Follow-up period	Conclusion	Ref
CD Induction	368 Patients with active CD (Cohort 1)	Vedolizumab 300 mg Week 0 and 2	14.5%a	31.4%b	6 weeks	At week 6, patients receiving vedolizumab more likely to attain remission	[27]
	747 Patients with active CD (Cohort 2)	Placebo	6.8%	25.7%
		Week 0 and 2 Open-label vedolizumab	17.7%	34.4%
CD Maintenance	461 Patients who responded to induction therapy with vedolizumab	Vedolizumab 300 mg every 8 weeks	39.0%c	43.5%e	52 weeks	Patients responding to induction therapy more likely to be in remission at week 52	[27]
		Vedolizumab 300 mg every 4 weeks	36.4%d	45.5%f
		Placebo	21.6%	30.1%
UC Induction	374 Patients with active UC (Cohort 1)	Vedolizumab 300 mg Week 0 and 2	47.1%g	16.9%h	6 weeks	Vedolizumab was more effective than placebo for induction therapy for UC	[28]
	521 Patients with active UC (Cohort 2)	Placebo	25.5%	5.4%
		Week 0 and 2
UC Maintenance	373 Patients who responded to induction therapy with vedolizumab	Vedolizumab 300 mg every 8 weeks.	41.8%i	56.6%k	52 weeks	Vedolizumab was more effective than placebo for maintenance therapy for UC	[28]
		Vedolizumab 300 mg every 4 weeks	44.8%j	52.0%l
		Placebo	15.9%	23.8%

^ap = 0.02 vs. placebo.

^bp = 0.23 vs. placebo.

^cp < 0.001 vs. placebo.

^dp = 0.004 vs. placebo.

^ep = 0.01 vs. placebo.

^fp = 0.005 vs. placebo.

^gp < 0.001 vs. placebo.

^hp = 0.001 vs. placebo.

ⁱp < 0.001 vs. placebo.

^jp < 0.001 vs. placebo.

^kp < 0.001 vs. placebo.

^lp < 0.001 vs. placebo.